EGFR and breast adenocarcinoma: A trend was recognized for the dual-combination of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] to exert slightly greater levels of selectively “targeted” anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) at the chemotherapeutic-equivalent concentrations of 10−9 M, 10−8 M and 10−7 M compared to gemcitabine-(C4-amide)-[EGFR] alone (Figure.